A randomized, open label, phase II study comparing pemetrexed plus cisplatin followed by pemetrexed versus pemetrexed alone in EGFR mutant NSCLC patients who have failed first-line EGFR TKI: KCSG-LU12-13.

Kwai Han Yoo,Jinhyun Cho,Ki Hyeong Lee,Keon Uk Park,Ki Hwan Kim,Eun Kyung Cho,Kyung A Kwon,H. K. Ahn,HyeRyun Kim,Hoon-Gu Kim,Ha Yeon Lee,Hwan-Jung Yun,Jin-Hyoung Kang,Jae-Heon Jeong,Moon Young Choi,Sin-Ho Jung,Jong Mu Sun,Jin Seok Ahn,Keunchil Park,Myung-Ju Ahn

A randomized, open label, phase II study comparing pemetrexed plus cisplatin followed by pemetrexed versus pemetrexed alone in EGFR mutant NSCLC patients who have failed first-line EGFR TKI: KCSG-LU12-13.

2016

9043Background: Various therapeutic strategies are available for NSCLC patients who develop disease progression on first-line EGFR-TKI. However, it has not been established which cytotoxic regimens...

Keywords:

Physical therapy
Pemetrexed
Phases of clinical research
Cisplatin
Cancer research
Medicine
open label
Mutant
Oncology
egfr tki
first line
Cytotoxic T cell
Internal medicine
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations